PTPRB and neoplasm: Of note, there are damaging mutations predicted to occur in CBFA2T3, CHEK2, FANCC, FLI1, ITPR1, MUC16, NF1, NUTM, PTPRB, PTPRR, SETX, and STK11IP in the virus-negative tumor, which may further promote tumor survival and evolution.